Erasmus School of Health Policy & Management
Assistant professor | Health Technology Assessment (HTA)
- thielen@eshpm.eur.nl
More information
Work
- Michiel Zietse, Luuk C Aalders, Leontine E A M M Spierings, Nikki De Rouw, Wouter Dercksen, Virgil A S H Dalm, Esther Oomen-de Hoop, Frederick W Thielen, Birgit C P Koch, Ron H J Mathijssen, Leni van Doorn & Roelof W F van Leeuwen (2025) - Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial - BMJ open, 15 (4), e102770 - doi: 10.1136/bmjopen-2025-102770 - [link]
- M. M.B. Horstink, D. R. Geel, , C. A. den Uil, P. E. Deetman, H. Endeman, A. Abdulla, T. M. Bosch, W. J.R. Rietdijk, F. W. Thielen, J. J. Haringman, P. van Vliet, T. A. Rijpstra, C. Bethlehem, A. Beishuizen, A. E. Muller, B. C.P. Koch, R. Zwinkels, N. Juffermans, N. G.M. Hunfeld, M. Kemper, M. van der Jagt, M. G.J. de Boer, L. Vloet, J. Elderman, I. Nutma, H. Buter, E. Van Haren, C. A. den Uil & C. Boly (2025) - Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial - BMC Infectious Diseases, 25 (1) - doi: 10.1186/s12879-025-10747-3 - [link]
- Michiel Zietse, Thirza Kooijman, Ruben Malmberg, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen, Roelof W F van Leeuwen & Frederick W Thielen (2025) - Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis - JCO Oncology Practice, OP2400804 - doi: 10.1200/OP-24-00804 - [link]
- Sejad Ayyoubi, Liesbeth Ruijgrok, Hugo van der Kuy, Renske Ten Ham & Frederick Thielen (2024) - What Does Pharmaceutical 3D Printing Cost?: A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency - PharmacoEconomics - Open, 9 (2), 207-215 - doi: 10.1007/s41669-024-00551-1 - [link]
- Michiel Zietse, Ruben Malmberg, Roelof W.F. van Leeuwen, Frederick W. Thielen & Carin A. Uyl – de Groot (2024) - The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective - Bmc Health Services Research, 24 (1) - doi: 10.1186/s12913-024-11719-0 - [link]
- R. J.S.D. Heine, F. W. Thielen, R. H.J. Mathijssen, R. W.F. van Leeuwen, M. G. Franken & C. A. Uyl-de Groot (2024) - Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab - PLoS ONE, 19 (2 February) - doi: 10.1371/journal.pone.0293264 - [link]
- Leona Hakkaart - van Roijen, Stijn Peeters, Tim Kanters, Pieter van Baal, Werner Brouwer, Ruben Drost, Silvia M.A.A. Evers, Job van Exel, Vivian Reckers-Droog, Nasr-Eddine Tannaoui, Frederick Thielen & Ben Wijnen (2024) - <b>Kostenhandleiding </b>voor economische evaluaties in de gezondheidszorg:: Methodologie en Referentieprijzen - [link]
- Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
- Lj Bakker, Fw Thielen, WK Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
- Ngoc Do & Frederick W. Thielen (2023) - Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View - Value in Health, 26 (4), 477-486 - doi: 10.1016/j.jval.2022.11.002 - [link]
- Frederick Thielen (2018) - Best Student Poster Presentation
- WF (Frederick) Thielen (2013) - ESST European Award for Aspiring Undergraduates
Advanced Health Economic Modelling
- Year Level
- master, master, master
- Year
- 2025
- Course Code
- GW4563M
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year Level
- master
- Year
- 2025
- Course Code
- GW4587M
Pharmaceutical Pricing and Market Access
- Year Level
- master, master, master, master
- Year
- 2025
- Course Code
- GW4575M
ESHPM HEPL-HE
- Year
- 2025
- Course Code
- GWMTTHEPL
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2025
- Course Code
- GW4555M
Master Thesis HE
- Year Level
- master, master
- Year
- 2025
- Course Code
- GW4592M
